Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Two other oral BTK inhibitors in development for MS – Merck KGaA’s evobrutinib and Sanofi’s tolebrutinib – have been linked to liver toxicity that resulted in the FDA placing them on ...

Merck KGaA's evobrutinib was the first BTK inhibitor to show proof-of-concept in a phase 2 MS trial, but failed two phase 3 trials in relapsing MS last year and was shelved. Novartis' remibrutinib ...

Immune kinases including, JAK1, JAK2, JAK3, TYK2 and BTK have shown clinical effects ... develop and commercialize small-molecule inhibitors of TAK1. June 20, 2024 Aqilion announced that Aqilion and ...

The FDA also granted approval to AstraZeneca’s another BTK inhibitor Calquence in combination ... AstraZeneca rose the most (4.4%), while Merck declined the most (3.5%). In the past six months ...

and Merck & Co are making substantial strides in the creation of cutting-edge therapies designed to enhance symptom management and improve long-term outcomes for CU patients. Furthermore, the ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.